Phosphodiesterase-4 Inhibition in the Management of Psoriasis

Author:

Crowley Erika L.1,Gooderham Melinda J.234

Affiliation:

1. Faculty of Medicine, University of British Columbia Okanagan, 3333 University Way, Kelowna, BC V1V 1V7, Canada

2. SKiN Centre for Dermatology, 775 Monaghan Rd, Peterborough, ON K9J 5K2, Canada

3. Probity Medical Research, 139 Union St E, Waterloo, ON N2J 1C4, Canada

4. Department of Medicine, Queen’s University, 99 University Ave, Kingston, ON K7L 3N6, Canada

Abstract

Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options. PDE4 inhibitors play a pivotal role in the inflammatory cascade by degrading cyclic adenosine monophosphate (cAMP), contributing to pro-inflammatory mediator production. Apremilast, an oral PDE4 inhibitor, is approved for psoriasis. While effective, its adverse effects can limit its utility. Roflumilast, a topical PDE4 inhibitor, was also recently approved for psoriasis and shows promise in clinical trials. Crisaborole, a PDE4 inhibitor approved for atopic dermatitis, has also been studied in psoriasis. This review summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management.

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference79 articles.

1. Diagnosis and Classification of Psoriasis;Raychaudhuri;Autoimmun. Rev.,2014

2. (2023, October 19). Chronic Plaque Psoriasis: Causes, Symptoms, and Treatment. Available online: https://dermnetnz.org/topics/chronic-plaque-psoriasis.

3. Patient Perspectives in the Management of Psoriasis: Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey;Lebwohl;J. Am. Acad. Dermatol.,2014

4. A Systematic Review of Worldwide Epidemiology of Psoriasis;Michalek;J. Eur. Acad. Dermatol. Venereol.,2017

5. Psychiatric Morbidity in Psoriasis: A Review;Russo;Australas. J. Dermatol.,2004

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3